Eslicarbazepine acetate in clinical practice. efficacy and safety results;Acetato de eslicarbazepina en la práctica clínica. resultados de efcacia y seguridad

Revista de Neurologia

Volumn 56, Issue 6, 2013, Pages 309-314

  Serrano Castro, Pedro J ^a   Payán Ortiz, Manuel ^a   Cimadevilla, José M ^b   Quiroga Subirana, Pablo ^a   Fernández Pérez, Javier ^a  

^a HOSPITAL TORRECÁRDENAS   (Spain)

^b UNIVERSITY OF ALMERÍA   (Spain)

Author keywords

Adjunctive treatment; Adults; Antiepileptic; Eslicarbazepine acetate; Partial seizures; Refractory epilepsy

Indexed keywords

ESLICARBAZEPINE ACETATE; HARKOSERIDE; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SEIZURE;

EID: 84876164664     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5606.2013031     Document Type: Article

References (13)

1. Mauri-Llerda JA. Acetato de eslicarbazepina: una nueva alternativa en el tratamiento de las crisis focales. Rev Neurol 2012; 54: 551-555.
2. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-151.
3. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. Te Department of Veterans Afairs Epilepsy Cooperative Study no. 264 Group. N Engl J Med 1992; 327: 765-771.
4. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on placebo, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007; 48: 497-504.
5. Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-463.
6. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-287.
7. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsia 2010; 89: 278-285.
8. Loureiro R, Freitas J, Correia F, Lopes J, Ramalheira J, Chaves J, et al. One year experience with eslicarbazepine acetate on a community hospital in Porto, Portugal. Epilepsia 2011; 52 (Suppl 6): S23-S263.
9. Kwan P, Arzimanoglou A, Berg A, Brodie MJ, Hauser WA, Mathern G, et al. Special report. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Terapeutic Strategies. Epilepsia 2010; 51: 1069-1077.
10. Serrano-Castro PJ, Sánchez-Álvarez JC. Controversias en torno a los nuevos fármacos antiepilépticos. Rev Neurol 2001; 32: 165-171.
11. Almeida L, Nunes T, Sicard E, Rocha JF, Falcão A, Brunet JS, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010; 121: 257-264.
12. Villanueva V, López-Gomáriz E, López-Trigo J, Palau J, García M, Villarroya T, et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 2012; 23: 298-304.
13. Soares-da-Silva P, Hebeisen S. Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine and carbamazepine. Epilepsia 2012; 53 (Suppl 5): S1-S280.